Myriad Genetics (MYGN) Invested Capital (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Invested Capital data on file, last reported at $457.7 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $457.7 million, down 40.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $457.7 million (down 40.11% YoY), and the FY2025 annual result was $487.9 million, down 34.13% from the prior year.
• Invested Capital slipped to $457.7 million in Q1 2026 per MYGN's latest filing, from $487.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $950.1 million in Q1 2022 and troughed at $447.5 million in Q2 2025.
• A 5-year average of $741.1 million and a median of $775.2 million in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital advanced 6.68% in 2024, then slumped 42.66% in 2025.
• A 5-year view of Invested Capital shows it stood at $885.8 million in 2022, then slipped by 7.24% to $821.7 million in 2023, then fell by 9.86% to $740.7 million in 2024, then slumped by 34.13% to $487.9 million in 2025, then declined by 6.19% to $457.7 million in 2026.
• Business Quant data shows MYGN's Invested Capital at $457.7 million in Q1 2026, $487.9 million in Q4 2025, and $492.3 million in Q3 2025.